Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucindolol - ARCA biopharma Inc

Next Previous
Drug Profile

Bucindolol - ARCA biopharma Inc

Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051

Latest Information Update: 07 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ARCA biopharma Inc; Medtronic
  • Class Anti-ischaemics; Antiarrhythmics; Benzonitrile; Heart failure therapies; Indoles; Phenyl ethers; Propanolamines; Small molecules; Vasodilators
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Atrial fibrillation
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 04 Jan 2022 Efficacy and safety data from phase IIb/III trial in Atrial fibrillation released by ARCA biopharma
  • 28 Jul 2021 Efficacy and pharmacodynamics data from a phase IIb/III trial in Atrial fibrillation released by ARCA BioPharm
  • 19 Mar 2021 ARCA Biopharma files for a patent applications for the use of bucindolol in the treatment of atrial fibrillation (AF) in patients with heart failure (HF) in undisclosed counties, prior to March 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top